HRP20171939T1 - Formulacija protutijela i režimi terapije - Google Patents

Formulacija protutijela i režimi terapije Download PDF

Info

Publication number
HRP20171939T1
HRP20171939T1 HRP20171939TT HRP20171939T HRP20171939T1 HR P20171939 T1 HRP20171939 T1 HR P20171939T1 HR P20171939T T HRP20171939T T HR P20171939TT HR P20171939 T HRP20171939 T HR P20171939T HR P20171939 T1 HRP20171939 T1 HR P20171939T1
Authority
HR
Croatia
Prior art keywords
antibody
seq
heavy chain
light chain
sequence
Prior art date
Application number
HRP20171939TT
Other languages
English (en)
Inventor
Dingjiang Liu
Holly Zhuohong Huang
David Andrew Martin
Christopher Boyd Russell
David H. Salinger
Scott Walter Baumgartner
Christopher J. Endres
Original Assignee
Kirin-Amgen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171939(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin-Amgen, Inc. filed Critical Kirin-Amgen, Inc.
Publication of HRP20171939T1 publication Critical patent/HRP20171939T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)

Claims (17)

1. Farmaceutska formulacija, koja sadrži vodenu otopinu pufera glutaminske kiseline i protutijela koje sadrži sekvencu varijabilne domene teškog lanca koja obuhvaća SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja obuhvaća SEQ ID NO:4, naznačena time da se navedeno protutijelo specifično veže na ljudski receptor A za IL-17, te što: a) navedena formulacija sadrži glutaminsku kiselinu u koncentraciji od 5-30 mM ± 0,2 mM; b) navedena formulacija ima pH 4,5-5,2 ± 0,2; c) navedena formulacija dalje sadrži 2-4% prolin (mas/v) i 0,005-0,02% (mas/v) polisorbat 20; d) navedeno protutijelo ima koncentraciju od 100 do 150 mg/ml.
2. Farmaceutska formulacija prema zahtjevu 1, naznačena time da protutijelo sadrži sekvencu teškog lanca koja obuhvaća SEQ ID NO:1 i sekvencu lakog lanca koja obuhvaća SEQ ID NO:2, ili alternativno, sekvencu teškog lanca koja obuhvaća SEQ ID NO:12 i sekvencu lakog lanca koja obuhvaća sekvencu SEQ ID NO:2.
3. Farmaceutska formulacija prema zahtjevu 1 ili zahtjevu 2, naznačena time da nadalje ima osmolarnost od 250 do 400 mOsm/L.
4. Farmaceutski kontejner, koji obuhvaća posudu i farmaceutsku formulaciju prema bilo kojem od zahtjeva 1 do 3, naznačena time da je navedena posuda bočica, boca, prethodno napunjena injekcija, ili prethodno napunjena autoinjektorska injekcija.
5. Komplet, naznačen time da sadrži jedan ili više farmaceutskih spremnika prema zahtjevu 4 i upute u vezi s njihovom upotrebom.
6. Farmaceutska formulacija prema bilo kojem od zahtjeva 1-3 naznačena time da je za upotrebu u postupku liječenja psorijaze kod humanog pacijenta, pri čemu je protutijelo u dozi od 70, 140, 210 ili 280 mg.
7. Farmaceutska formulacija za upotrebu prema zahtjevu 6, naznačena time da se navedenom pacijentu daje doza od 70 do 280 mg navedenog protutijela svakog tjedna, svaka dva tjedna i/ili svakog mjeseca.
8. Farmaceutska formulacija za upotrebu prema zahtjevu 7, naznačena time da se doza od 140 mg navedenog protutijela daje pacijentima koji imaju tjelesnu masu koja je manja od ili približno jednaka 100 kg, te da se doza od 210 mg navedenog protutijela daje pacijentima koji imaju tjelesnu masu koja je veća od 100 kg.
9. Farmaceutska formulacija za upotrebu prema bilo kojem od zahtjeva 6 do 8, naznačena time da se psorijaza bira iz skupine koja sadrži: a) psorijazu koja dovodi do stvaranja plaka; b) umjerenu psorijazu do psorijaze s ozbiljnim simptomima koja dovodi do stvaranja plaka; c) kroničnu umjerenu psorijazu do psorijaze s ozbiljnim simptomima koja dovodi do stvaranja plaka i navedeni pacijenti su kandidati za sistemsku terapiju ili fototerapiju; i d) kroničnu umjerenu psorijazu do psorijaze s ozbiljnim simptomima koja dovodi do stvaranja plaka i što navedeni pacijenti ne reagiraju na, imaju kontraindikaciju prema, ili su netolerantni na druge sistemske terapije uključujući ciklosporin, metotreksat, i psoralen plus fototerapiju ultraljubičastim-A zračenjem.
10. Farmaceutska formulacija za upotrebu prema bilo kojem od zahtjeva 6 do 9, naznačena time da navedena farmaceutska formulacija sadrži oko 140 mg/ml navedenog protutijela, koje je formulirano s 10 ± 0,2 mM glutaminskom kiselinom, 3 ± 0,2% (mas/v) L-prolinom, 0,01 ± 0,002% (mas/v) polisorbatom 20, pH 4,8 ± 0,2.
11. Farmaceutska formulacija za upotrebu prema bilo kojem od zahtjeva 6-10, naznačena time da se navedena farmaceutska formulacija daje subkutano, intradermalno, intramuskularno, i/ili intravenozno.
12. Farmaceutski pripravak koji sadrži protutijelo od oko 100-150 mg/ml, koje je formulirano s: i) glutaminskom kiselinom u koncentraciji od 10 mM; ii) pH od 4,8 ± 0,2; iii) 3% prolinom (mas/v) i 0,01% (mas/v) polisorbatom 20; pri čemu se navedeno protutijelo bira iz skupine koja sadrži: a) protutijelo koje sadrži sekvencu varijabilne domene teškog lanca koja sadrži SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja sadrži SEQ ID NO:4, pri čemu se navedeno protutijelo specifično veže za ljudski receptor A za IL-17; i b) protutijelo koje sadrži sekvencu teškog lanca koja sadrži SEQ ID NO:1 i sekvencu lakog lanca koji sadrži SEQ ID NO:2, ili alternativno, sekvencu teškog lanca koja sadrži SEQ ID NO:12 i sekvencu lakog lanca koja sadrži SEQ ID NO:2, za upotrebu u postupku liječenja psorijaznog artritisa kod humanog pacijenta, pri čemu je protutijelo u dozi od 70, 140, 210 ili 280 mg.
13. Farmaceutski pripravak koji sadrži protutijelo od oko 100-150 mg/ml, koje je formulirano s: i) glutaminskom kiselinom u koncentraciji od 10 mM; ii) pH od 4,8 ± 0,2; iii) 3% prolinom (mas/v) i 0,01% (mas/v) polisorbatom 20; pri čemu se navedeno protutijelo bira iz skupine koja sadrži: a) protutijelo koje sadrži sekvencu varijabilne domene teškog lanca koja sadrži SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja sadrži SEQ ID NO:4, pri čemu se navedeno protutijelo specifično veže za ljudski receptor A za IL-17; i b) protutijelo koje sadrži sekvencu teškog lanca koja sadrži SEQ ID NO: 1 i sekvencu lakog lanca koji sadrži SEQ ID NO:2, ili alternativno, sekvencu teškog lanca koja sadrži SEQ ID NO:12 i sekvencu lakog lanca koja sadrži SEQ ID NO:2, za upotrebu u postupku liječenja astme kod humanog pacijenta, što je navedeno protutijelo u dozi od 70, 140, 210 ili 280 mg.
14. Farmaceutski pripravak koji sadrži protutijelo od oko 100-150 mg/ml, koje je formulirano s: i) glutaminskom kiselinom u koncentraciji od 10 mM; ii) pH od 4,8 ± 0,2; iii) 3% prolinom (mas/v) i 0,01% (mas/v) polisorbatom 20; pri čemu se navedeno protutijelo bira iz skupine koja sadrži: a) protutijelo koje sadrži sekvencu varijabilne domene teškog lanca koja sadrži SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja sadrži SEQ ID NO:4, pri čemu se navedeno protutijelo specifično veže za ljudski receptor A za IL-17; i b) protutijelo koje sadrži sekvencu teškog lanca koja sadrži SEQ ID NO: 1 i sekvencu lakog lanca koji sadrži SEQ ID NO:2, ili alternativno, sekvencu teškog lanca koja sadrži SEQ ID NO:12 i sekvencu lakog lanca koja sadrži SEQ ID NO:2, za upotrebu u postupku liječenja ankilozirajućeg spondilitisa kod humanog pacijenta, što je navedeno protutijelo u dozi od 70, 140, 210 ili 280 mg.
15. Farmaceutski pripravak koji sadrži protutijelo od oko 100-150 mg/ml, koje je formulirano s: i) glutaminskom kiselinom u koncentraciji od 10 mM; ii) pH od 4,8 ± 0,2; iii) 3% prolinom (mas/v) i 0,01% (mas/v) polisorbatom 20; pri čemu se navedeno protutijelo bira iz skupine koja sadrži: a) protutijelo koje sadrži sekvencu varijabilne domene teškog lanca koja sadrži SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja sadrži SEQ ID NO:4, pri čemu se navedeno protutijelo specifično veže za ljudski receptor A za IL-17; i b) protutijelo koje sadrži sekvencu teškog lanca koja sadrži SEQ ID NO: 1 i sekvencu lakog lanca koji sadrži SEQ ID NO:2, ili alternativno, sekvencu teškog lanca koja sadrži SEQ ID NO:12 i sekvencu lakog lanca koja sadrži SEQ ID NO:2, za upotrebu u postupku liječenja multiple skleroze kod humanog pacijenta, što je navedeno protutijelo u dozi od 70, 140, 210 ili 280 mg.
16. Formulacija za upotrebu prema bilo kojem od zahtjeva 12 do 15, naznačena time da navedena farmaceutska formulacija nadalje sadrži oko 140 mg/ml navedenog protutijela i što navedeni lijek ima viskoznost od 5 do 7 cP na 25 stupnjeva C.
17. Formulacija za upotrebu prema bilo kojem od zahtjeva 12 do 16, naznačena time da se farmaceutska formulacija daje subkutano, intradermalno, intramuskularno, i/ili intravenozno.
HRP20171939TT 2010-01-15 2011-01-12 Formulacija protutijela i režimi terapije HRP20171939T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29538710P 2010-01-15 2010-01-15
US42205910P 2010-12-10 2010-12-10
PCT/US2011/020985 WO2011088120A1 (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens
EP11705713.3A EP2523688B1 (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens

Publications (1)

Publication Number Publication Date
HRP20171939T1 true HRP20171939T1 (hr) 2018-03-23

Family

ID=43858045

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171939TT HRP20171939T1 (hr) 2010-01-15 2011-01-12 Formulacija protutijela i režimi terapije

Country Status (38)

Country Link
US (5) US8883151B2 (hr)
EP (3) EP3632466A1 (hr)
JP (2) JP5743234B2 (hr)
KR (1) KR101766936B1 (hr)
CN (1) CN102821787B (hr)
AR (1) AR079903A1 (hr)
AU (3) AU2011205402B2 (hr)
BR (1) BR112012017150B1 (hr)
CA (1) CA2787128C (hr)
CL (1) CL2012001966A1 (hr)
CO (1) CO6640206A2 (hr)
CR (1) CR20120419A (hr)
CY (2) CY1119852T1 (hr)
DK (2) DK2523688T3 (hr)
EA (2) EA031209B9 (hr)
ES (2) ES2753216T3 (hr)
HR (1) HRP20171939T1 (hr)
HU (2) HUE046670T2 (hr)
IL (1) IL220602B (hr)
IN (1) IN2012DN06720A (hr)
LT (2) LT3295957T (hr)
MA (1) MA33989B1 (hr)
MX (1) MX349856B (hr)
MY (1) MY182680A (hr)
NO (1) NO2523688T3 (hr)
NZ (1) NZ601125A (hr)
PE (1) PE20121691A1 (hr)
PH (1) PH12012501364A1 (hr)
PL (2) PL3295957T3 (hr)
PT (2) PT2523688T (hr)
RS (2) RS59743B1 (hr)
SG (2) SG182468A1 (hr)
SI (2) SI3295957T1 (hr)
TN (1) TN2012000335A1 (hr)
TW (1) TWI554282B (hr)
UA (1) UA112288C2 (hr)
WO (1) WO2011088120A1 (hr)
ZA (1) ZA201205167B (hr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EA031209B9 (ru) * 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
CA2788863C (en) * 2010-02-04 2020-07-07 Csl Behring Ag Immunoglobulin preparation
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
CN103339145A (zh) * 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
EP2694100A4 (en) * 2011-04-07 2014-10-01 Glaxosmithkline Llc FORMULATIONS HAVING REDUCED VISCOSITY
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP3492099A1 (en) * 2011-11-23 2019-06-05 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
PE20142275A1 (es) * 2012-03-07 2015-01-08 Lilly Co Eli Formulacion de anticuerpo il-17
AU2013262083A1 (en) 2012-05-14 2014-11-06 Novo Nordisk A/S Stabilised protein solutions
EP3689369A1 (en) 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
WO2014143540A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
MY184189A (en) * 2014-03-31 2021-03-24 Amgen K A Inc Methods of treating nail and scalp psoriasis
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
WO2016031250A1 (en) 2014-08-26 2016-03-03 Kirin-Amgen, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EP3193171B1 (en) * 2014-09-10 2019-05-29 NOF Corporation Use of a protein adsorption inhibitor and method for inhibiting protein adsorption
MX388043B (es) 2014-12-03 2025-03-19 Csl Behring Ag Producto farmacéutico con estabilidad incrementada que comprende inmunoglobulinas.
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
RU2018113694A (ru) 2015-09-17 2019-10-17 Эмджен Инк. Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
WO2017077391A2 (en) 2015-11-04 2017-05-11 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
EP3446178A4 (en) 2016-04-19 2020-01-22 Sage Electrochromics, Inc. Electrochromic device including a transparent conductive oxide layer and a bus bar and a process of forming the same
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
CA2974531A1 (en) * 2017-07-26 2019-01-26 Michael Giroux Safety anchor and roof vent
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CN112689643A (zh) 2018-07-13 2021-04-20 阿斯特捷利康合作创业有限责任公司 用布雷库单抗治疗溃疡性结肠炎
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
JP2022547678A (ja) * 2019-09-11 2022-11-15 ボシュ ヘルス アイルランド リミテッド Ｉｌ－１７ｒａ抗体を用いた非アルコール性脂肪性肝疾患（ｎａｆｌｄ）の治療方法
PE20230115A1 (es) * 2020-02-18 2023-01-27 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos
CN112891530B (zh) * 2020-06-19 2021-08-24 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂
CN117615788A (zh) * 2021-05-12 2024-02-27 安奈普泰斯生物有限公司 抗体组合物
WO2023240071A1 (en) * 2022-06-06 2023-12-14 Fusion Pharmaceuticals Inc. Methods of dosing therapeutic agents

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000835A (en) 1911-06-19 1911-08-15 Stewart A Minnick Calipers.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
ATE119942T1 (de) 1989-05-18 1995-04-15 Yeda Res & Dev Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
AU642938B2 (en) 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
DK0835939T3 (da) 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
CA2100329C (en) 1991-01-18 2009-09-29 David F. Carmichael Methods for treating tumor necrosis factor mediated diseases
DE69233069T2 (de) 1991-03-15 2003-11-27 Amgen Inc., Thousand Oaks Pegylation von polypeptiden
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (en) 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
AU671116B2 (en) 1992-03-30 1996-08-15 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
JPH07504203A (ja) 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
JP4373495B2 (ja) 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
EP0839196B1 (en) 1995-07-19 2005-05-11 Genetics Institute, LLC Human ctla-8 and uses of ctla-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
DE69739375D1 (de) 1996-11-27 2009-06-04 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid-erzeugung
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU9482498A (en) 1997-09-17 1999-04-05 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ATE464062T1 (de) 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
JP2003526370A (ja) 2000-03-16 2003-09-09 アムジェン インコーポレーテッド Ｉｌ−１７レセプター様分子およびその使用
TWI322154B (en) 2000-03-16 2010-03-21 Amgen Inc Il-17 receptor like molecules and uses thereof
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
JP2004517918A (ja) 2000-10-18 2004-06-17 イミュネックス・コーポレーション Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
WO2004002519A1 (en) 2002-06-27 2004-01-08 Smithkline Beecham Corporation Methods of treating or preventing ibd with il-18
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
JP2007501252A (ja) 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調整剤を含有する製剤
GB0321703D0 (en) * 2003-09-16 2003-10-15 Imerys Minerals Ltd Surface modified fillers for polymer resin compositions
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
CN101014664B (zh) 2004-06-04 2012-10-10 设计者分子公司 可自由基固化的聚酯及其使用方法
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CA2596986A1 (en) 2005-02-14 2006-08-24 Wyeth Use of il-17f in diagnosis and therapy of airway inflammation
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
EP2322219A3 (en) 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
CA2624763A1 (en) 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
UA97234C2 (ru) 2005-11-01 2012-01-25 Уайєт Раствор хлорида натрия для восстановления влагосодержания композиции лиофилизированного фактора ix
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd ANTIBODY-CONTAINING STABILIZING PREPARATION
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CN101541833B (zh) * 2006-10-02 2014-01-29 麒麟-安姆根有限公司 Il-17受体a抗原结合蛋白质
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CA2666842A1 (en) 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
CA2672902C (en) * 2006-12-21 2012-11-27 Amgen Inc. Formulations
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
EP2170958A1 (en) 2007-06-13 2010-04-07 Amgen Inc. Il-17 heteromeric receptor complex
US20110014676A1 (en) 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
AU2008289225A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and Fc-fusion molecules using polycations
CN104151428B (zh) 2008-02-21 2017-07-14 麒麟-安姆根有限公司 Il‑17ra‑il‑17rb拮抗物及其用途
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EA031209B9 (ru) 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
PT2625199T (pt) 2010-10-08 2018-02-28 Novartis Ag Métodos de tratamento de psoríase usando antagonistas de il-17
EP3214442A1 (en) 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a
BR112013025845A2 (pt) * 2011-04-07 2018-09-04 Glaxosmithkline Llc formulações com viscosidade reduzida
EP2694100A4 (en) * 2011-04-07 2014-10-01 Glaxosmithkline Llc FORMULATIONS HAVING REDUCED VISCOSITY
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
MY184189A (en) 2014-03-31 2021-03-24 Amgen K A Inc Methods of treating nail and scalp psoriasis
WO2016031250A1 (en) 2014-08-26 2016-03-03 Kirin-Amgen, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy

Also Published As

Publication number Publication date
LT2523688T (lt) 2018-03-12
CL2012001966A1 (es) 2013-01-18
DK2523688T3 (en) 2017-12-04
EA031209B9 (ru) 2021-11-19
US8883151B2 (en) 2014-11-11
KR101766936B1 (ko) 2017-08-09
MA33989B1 (fr) 2013-02-01
US11505612B2 (en) 2022-11-22
PL2523688T3 (pl) 2018-04-30
WO2011088120A8 (en) 2012-09-13
EP3295957B1 (en) 2019-08-07
CA2787128A1 (en) 2011-07-21
TN2012000335A1 (en) 2013-12-12
SI2523688T1 (en) 2018-03-30
US20130022621A1 (en) 2013-01-24
KR20120118036A (ko) 2012-10-25
EP3632466A1 (en) 2020-04-08
PE20121691A1 (es) 2012-12-14
CR20120419A (es) 2012-11-29
PL3295957T3 (pl) 2020-03-31
IN2012DN06720A (hr) 2015-10-23
PT2523688T (pt) 2018-01-05
US20230192873A1 (en) 2023-06-22
AU2011205402A1 (en) 2012-07-12
MX2012008213A (es) 2012-11-06
AU2015202023B2 (en) 2017-05-18
EA031209B1 (ru) 2018-12-28
CY1122466T1 (el) 2020-10-14
ZA201205167B (en) 2013-03-27
BR112012017150B1 (pt) 2022-03-03
NO2523688T3 (hr) 2018-03-10
UA112288C2 (uk) 2016-08-25
US20150017184A1 (en) 2015-01-15
SG182468A1 (en) 2012-08-30
TWI554282B (zh) 2016-10-21
LT3295957T (lt) 2020-01-27
SI3295957T1 (sl) 2020-02-28
PH12012501364A1 (en) 2012-10-22
AU2015202023A1 (en) 2015-05-14
MY182680A (en) 2021-01-29
EP3295957A1 (en) 2018-03-21
CN102821787B (zh) 2015-07-29
JP2013517277A (ja) 2013-05-16
CN102821787A (zh) 2012-12-12
AR079903A1 (es) 2012-02-29
RS56781B1 (sr) 2018-04-30
EP2523688A1 (en) 2012-11-21
EA201290653A1 (ru) 2013-02-28
HUE035618T2 (en) 2018-05-28
PT3295957T (pt) 2019-11-12
US10072085B2 (en) 2018-09-11
CY1119852T1 (el) 2018-06-27
JP2015052017A (ja) 2015-03-19
EP2523688B1 (en) 2017-10-11
AU2017216579A1 (en) 2017-09-07
CA2787128C (en) 2019-06-11
NZ601125A (en) 2014-08-29
EA201891433A2 (ru) 2018-11-30
ES2652637T3 (es) 2018-02-05
DK3295957T3 (da) 2019-10-14
MX349856B (es) 2017-08-16
JP5743234B2 (ja) 2015-07-01
US10808033B2 (en) 2020-10-20
ES2753216T3 (es) 2020-04-07
AU2011205402B2 (en) 2015-02-05
EA201891433A3 (ru) 2019-02-28
WO2011088120A9 (en) 2012-08-09
SG10201604093XA (en) 2016-07-28
TW201129382A (en) 2011-09-01
WO2011088120A1 (en) 2011-07-21
US20200399384A1 (en) 2020-12-24
IL220602B (en) 2019-03-31
BR112012017150A2 (pt) 2017-10-10
CO6640206A2 (es) 2013-03-22
US20180346583A1 (en) 2018-12-06
RS59743B1 (sr) 2020-02-28
HUE046670T2 (hu) 2020-03-30

Similar Documents

Publication Publication Date Title
HRP20171939T1 (hr) Formulacija protutijela i režimi terapije
HRP20231282T1 (hr) Stabilna formulacija antitijela
BR112014008551A2 (pt) conjunto de válvulas para uso com recipiente de líquido e frasco de medicamento
JP2017031213A5 (hr)
HRP20110148T1 (hr) Koncentrirane otopine metotreksata
ES2521565T3 (es) Composiciones y métodos para el tratamiento de la esclerosis múltiple
HRP20211520T1 (hr) Postupci i pripravci za dostavu iduronat-2-sulfataze u središnji živčani sustav
AR109494A1 (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
ES2706059T3 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y derivado de L-arginina y una inyección que incluye la composición
FI3757126T3 (fi) Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla
IL291556B2 (en) Methods and compositions for administration of arylsulfatase A to the central nervous system
HRP20240082T1 (hr) Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
AU2023251529A1 (en) Therapeutic Antibody Formulation
RU2014127298A (ru) Применения иммуноконъюгатов, мишенью которых является cd138
JP2011527301A5 (hr)
HRP20161221T1 (hr) Tr1 stanice za liječenje artritičnih stanja
CL2011001178A1 (es) Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
JP7398958B2 (ja) 安定的抗ｏｓｍｒ抗体製剤
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
JP2020527540A5 (hr)
CY1113683T1 (el) Συστημα συσκευασιας για φαρμακευτικες συνθεσεις και kit για ενδοφλεβια χορηγηση
AR068531A1 (es) Dosis fija por inyeccion unica para ocrelizumab (2h7). uso de rituximab. formulacion farmaceutica. kit.
Gopalakrishna et al. Long-acting injectable aripiprazole: how might it fit in our tool box?
NZ703919A (en) Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins